Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 19, Pages E2646-E2654
Publisher
Proceedings of the National Academy of Sciences
Online
2016-04-19
DOI
10.1073/pnas.1604268113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
- (2016) Flora Peyvandi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
- (2015) Eric F. Zhu et al. CANCER CELL
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
- (2015) Rony Dahan et al. CANCER CELL
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals
- (2015) M. N. McCracken et al. CLINICAL CANCER RESEARCH
- Splenic Dendritic Cells Survey Red Blood Cells for Missing Self-CD47 to Trigger Adaptive Immune Responses
- (2015) Tangsheng Yi et al. IMMUNITY
- “Velcro” Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis
- (2015) Chia Chi M. Ho et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy
- (2014) D. R. Soto-Pantoja et al. CANCER RESEARCH
- Signal-regulatory proteinαfrom the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells
- (2014) Lai Shan Kwong et al. IMMUNOLOGY
- Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Nanobody-based products as research and diagnostic tools
- (2014) Thomas De Meyer et al. TRENDS IN BIOTECHNOLOGY
- The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target
- (2013) A. Neil Barclay et al. Annual Review of Immunology
- Neutrophils mediate antibody-induced antitumor effects in mice
- (2013) M. Albanesi et al. BLOOD
- CD271 on Melanoma Cell Is an IFN-γ-Inducible Immunosuppressive Factor that Mediates Downregulation of Melanoma Antigens
- (2013) Junpei Furuta et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
- (2013) Munir Akkaya et al. PLoS One
- Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
- (2013) D. Tseng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
- (2013) K. Weiskopf et al. SCIENCE
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
- (2012) Mark P Chao et al. CURRENT OPINION IN IMMUNOLOGY
- Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts
- (2012) Alexandre P.A. Theocharides et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
- (2012) Xuanming Yang et al. MOLECULAR THERAPY
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction
- (2011) X. W. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- IAP inhibitors enhance co-stimulation to promote tumor immunity
- (2010) Michael Dougan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
- (2010) M. P. Chao et al. Science Translational Medicine
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
- (2008) Richard K. Tsai et al. JOURNAL OF CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started